Genomics Firm Phosphorus Takes on At-Home COVID Testing

Phosphorus is a biotechnology company that uses genomics as a preventive mechanism to avoid genetic diseases. The company was founded in 2016 by Alexander Bisignano and Santiago Munne. Phosphorus specializes in genomics, genetic testing, and bioinformatics and is headquartered in New York. A team of scientists spearheads the company’s operations under the leadership of Alexander Bisignano, the CEO of Phosphorus.

By exploiting the human genome’s power, human health can be improved, which is in line with the company’s mission. The company offers cost-effective genetic tests of excellent quality. Phosphorus diagnostic tests provide a diagnosis of genetic diseases. Some of the Phosphorus Diagnostics tests include cardiology, oncology, lipidology, pharmacogenetics, neurology, fertility, and ophthalmology.

The company also offers PhosphorusONE, a comprehensive genomic test. This genetic test identifies health risks associated with genetic conditions such as heart disease, vision loss, and cancer, among other conditions. The test analyzes 375 genes, among which 175 cover drug interaction and 170 cover inherited conditions. This genetic test is invaluable to your health, as one can take preventive measures before the onset of major health issues. This genetic analysis also ascertains the likelihood of developing adverse reactions to drugs. Phosphorus Genomics tests use Next Generation Sequencing (NGS) technology, which it provides to hospitals and healthcare providers.

Since the emergence of COVID-19, the company has shifted to focus on the virus. Its primary objective is improving human health. Phosphorus has the technology and the capacity to perform COVID-19 tests. In addition, Phosphorus Genomics’s experience and expertise are of great significance in conducting COVID-19 tests. The company views COVID-19 testing as a measure to help life get back to normal and to aid in the reopening of the country.

The saliva test is one of the modes of COVID-19 testing available at Phosphorus. On August 6, 2020, Phosphorus announced that the US Food and Drug Administration (FDA) had granted the at-home sample collection kit the Emergency Use Authorization (EUA). It is the second company to be granted an EUA request for at-home saliva collection for COVID-19 testing.

The saliva-based collection method is simple and more convenient compared to the swab-based collection technique. A person can perform the test at home by ordering the home collection kit online. The online ordering platform requires consumers to complete medical questionnaires that are reviewed by a physician. On approval, the saliva collection kit is dispatched to the consumer’s address. After sample collection, the consumer submits the specimen to a laboratory for analysis. The submission of test results takes 72 hours, with consultation from a physician who provides guidance regarding the results and offers any necessary treatment.

The sample collection kit uses saliva as the specimen and detects nucleic acid from SARS-COV-2. The at-home sample collection kit is limited to detecting the presence of SARS-COV-2 only, not other viruses or pathogens. This mode of testing is safe due to limited exposure during sample collection.

Phosphorus follows testing protocols which use strict standards that give reliable results. Phosphorus diagnostic tests for COVID-19 are fully compliant with the FDA guidelines. The Phosphorus laboratory located in Secaucus, New Jersey, develops the saliva collection kits. The laboratory is CLIA-certified and CAP-accredited, licensed to operate in all 50 states.

Phosphorus, together with BiolQ, a healthcare and clinical adherence technology company, created a partnership that majors in the provision of EUA-authorized at-home saliva test kits. These kits include a Phosphorus saliva collection kit and specimen return package.

BiolQ’s expertise in health technology takes charge of digital symptoms, contact tracing, and follow-up care. This mode of testing is a critical need of government agencies and employers. It has resulted in the increased use of at-home sample collection kits and enhanced screening for COVID-19. Phosphorus’s alliance with BiolQ will expand COVID-19 testing networks to ensure that people have access to reliable and efficient COVID-19 tests.